[go: up one dir, main page]

MX2012004622A - Adyuvante para vacunas, vacunas que lo comprenden y usos. - Google Patents

Adyuvante para vacunas, vacunas que lo comprenden y usos.

Info

Publication number
MX2012004622A
MX2012004622A MX2012004622A MX2012004622A MX2012004622A MX 2012004622 A MX2012004622 A MX 2012004622A MX 2012004622 A MX2012004622 A MX 2012004622A MX 2012004622 A MX2012004622 A MX 2012004622A MX 2012004622 A MX2012004622 A MX 2012004622A
Authority
MX
Mexico
Prior art keywords
adjuvant
vaccines
polypeptide
parts
lipidated
Prior art date
Application number
MX2012004622A
Other languages
English (en)
Inventor
Mirta L Coria
Karina A Pasquevich
Andres E Ibanez
Guillermo H Giambartolomei
Juliana Cassataro
Maria Victoria Delpino
Original Assignee
Consejo Nac Invest Cient Tec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec filed Critical Consejo Nac Invest Cient Tec
Publication of MX2012004622A publication Critical patent/MX2012004622A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Adyuvante para vacunas que comprende un polipéptido no lipidado de la membrana externa (Omp) de bacterias, en donde las bacterias pueden ser del género Brucella. El adyuvante puede ser un polipéptido modificado, o puede ser por ejemplo el polipéptido Omp 1 9S o Omp 1 6S, partes del mismo, o mezclas de ambos. En una realización preferida el adyuvante es el polipéptido no lipidado comprendido en la SEQ ID N 1 o partes de la misma. En otra realización preferida el adyuvante es el polipéptido no lipidado comprendido en la SEQ ID N 2 o partes de la misma.
MX2012004622A 2009-10-19 2010-10-18 Adyuvante para vacunas, vacunas que lo comprenden y usos. MX2012004622A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP090104015A AR073907A1 (es) 2009-10-19 2009-10-19 Adyuvante para vacunas, que comprende un polipeptido no lipidado de la membrana externa (omp) de bacterias, vacunas que lo comprenden y usos
PCT/ES2010/070667 WO2011048248A1 (es) 2009-10-19 2010-10-18 Adyuvante para vacunas, vacunas que lo comprenden y usos.

Publications (1)

Publication Number Publication Date
MX2012004622A true MX2012004622A (es) 2012-05-08

Family

ID=43566830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004622A MX2012004622A (es) 2009-10-19 2010-10-18 Adyuvante para vacunas, vacunas que lo comprenden y usos.

Country Status (10)

Country Link
US (1) US9511137B2 (es)
EP (1) EP2491946B1 (es)
CN (1) CN102711815B (es)
AR (1) AR073907A1 (es)
BR (1) BR112012009239B1 (es)
CA (1) CA2778359C (es)
DK (1) DK2491946T3 (es)
ES (1) ES2542973T3 (es)
MX (1) MX2012004622A (es)
WO (1) WO2011048248A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106117365B (zh) * 2016-06-23 2018-07-27 湖南农业大学 抗猪链球菌病且具有自身免疫活性的融合蛋白及其制备和应用
CN106188307B (zh) * 2016-07-06 2019-01-04 长沙爱科博生物科技有限公司 一种融合蛋白、其制备方法及一种猪用口服疫苗或药物
CN107375922B (zh) * 2017-07-20 2020-06-09 南京农业大学 一种水溶性复合免疫佐剂及猪圆环病毒病疫苗
CN111936166B (zh) * 2018-02-09 2024-10-22 国家科学与技术研究理事会(Conicet) 用于药物递送的免疫调节和免疫刺激多肽
CN109486846B (zh) * 2018-12-29 2021-08-20 山东农业大学 一种布鲁氏菌三种基因重组质粒、构建方法及其在大肠杆菌中的表达和应用
CN114073762B (zh) * 2020-08-12 2023-07-21 中国人民解放军军事科学院军事医学研究院 一种含有Omp19和VirB8蛋白的布鲁氏菌病双组分疫苗
CN115267204A (zh) * 2022-08-02 2022-11-01 中国农业科学院北京畜牧兽医研究所 一种评估羊群是否免疫布鲁氏菌病疫苗的方法及试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816844A1 (fr) * 2000-11-17 2002-05-24 Pf Medicament Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur et/ou adjuvant
ES2190350B1 (es) * 2001-07-31 2005-01-01 Jose Instituto Cientifico Y Tecnologico De Navarra, S.A(67%) Composicion de vacuna frente a la brucelosis que comprende microparticulas de poli (e-caprolactona) como adyuvante.

Also Published As

Publication number Publication date
EP2491946A4 (en) 2013-06-19
ES2542973T3 (es) 2015-08-13
WO2011048248A1 (es) 2011-04-28
CN102711815B (zh) 2015-05-20
EP2491946B1 (en) 2015-04-22
US20120258145A1 (en) 2012-10-11
CN102711815A (zh) 2012-10-03
BR112012009239A2 (pt) 2017-06-06
BR112012009239B1 (pt) 2021-10-13
DK2491946T3 (en) 2015-07-27
US9511137B2 (en) 2016-12-06
EP2491946A1 (en) 2012-08-29
CA2778359C (en) 2019-07-16
CA2778359A1 (en) 2011-04-28
AR073907A1 (es) 2010-12-09

Similar Documents

Publication Publication Date Title
MX2012004622A (es) Adyuvante para vacunas, vacunas que lo comprenden y usos.
MX351247B (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EP4219566A3 (en) Recombinant rsv antigens
MX2011009515A (es) Ensamble de hombro invertido inductor de movimiento.
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
MX2009008617A (es) Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
MX2009005460A (es) (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
MX2010008423A (es) Tratamiento de infecciones microbianas.
MX2010002867A (es) Cepas de micoplasma atenuadas vivas.
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
MX2010000864A (es) Vacuna de celulas enteras estafilococcicas inactivadas.
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
NZ594011A (en) Deoxyactagardine derivatives
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
EP1572918A4 (en) SYNTHETIC GLYCOLIPOPEPTIDES AS VACCINES
ATE523204T1 (de) Cd44v6-peptide als bakterielle infektionsinhibitoren
MX2009003300A (es) Vectores de rhinovirus recombinantes.
WO2009077744A3 (en) Vaccines for brucellosis
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
WO2009105192A3 (en) Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax
WO2007086898A3 (en) Methods and compositions related to anthrax spore glycoproteins
MX2009003751A (es) Proteina ipad de shigella y su uso como vacuna contra infeccion por shigella.